AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2022 Issue 4; New/Revised ICD-10-PCS Codes Section X – New Technology
Transfusion of New Therapeutic Substances
Effective October 1, 2022, new substance values were added to code Table XW1, Transfusion of Anatomical Regions, for the four substances listed below. This change results in eight new codes that capture administration in the peripheral and central veins. Please note all of the substances below have a qualifier of 8, New Technology Group 8.Body Part Approach Device/Substance/Technology Qualifier 3 Peripheral Vein 4 Central Vein 3 Percutaneous B Betibeglogene Autotemcel C Omidubicel F OTL-103 G OTL-200 8 New Technology Group 8 Betibeglogene AutotemcelBetibeglogene autotemcel is an autologous hematopoietic stem cell transplant-based ex vivo gene therapy for treatment of...
Subscribe or sign in to view the full article.
Article Overview
This article covers an ICD-10-PCS coding update effective October 1, 2022, focused on new substance values added for transfusion procedures. It is intended for coding professionals and others who track inpatient procedure code changes, especially those working with hematology, gene therapy, and cell therapy services. The article provides a high-level overview of the substances involved, the affected procedural structure, and the coding context for the update.
Why This Topic Matters
It helps readers identify an official procedure-code change affecting reporting of newer therapeutic substances and understand the scope of the update at a general level.
Article Sections
-
ICD-10-PCS Update Overview
Introduces the effective date of the update and the procedural table affected by the new substance values. Summarizes the general scope of the code changes.
-
Betibeglogene Autotemcel
Provides background on one of the newly referenced therapeutic substances and its clinical context.
-
Omidubicel
Provides background on another newly referenced therapeutic substance and its clinical context.
-
OTL-103
Describes a gene-based cell therapy product included in the update and its clinical context.
-
OTL-200
Describes another gene-based cell therapy product included in the update and its clinical context.
What You Will Learn
- Which general ICD-10-PCS area was updated
- What types of therapeutic substances are included in the update
- How the article frames the clinical context for the referenced products
- What effective date is associated with the coding change
Who Should Read This
- Inpatient coding professionals
- Health information management staff
- Clinical coding educators
- CDI specialists
- Revenue cycle teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com